explore -WSS

explore

author：entertainment 2025-09-06 04:41:47 - browse：51395

he exterior of the U.S. Capitol building is seen at sunrise — Sarah Silbiger/Getty Images

WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： This gene therapy has record $4.25 million price. It's saved children.

WSS

Gilead might be held responsible for not developing a drug

Medicare threatens to cut off funding for HCA's Mission hospital

Biogen Alzheimer’s drug launch off to slow start

Key House Republican on health care plans exit from Congress

Gilead might be held responsible for not developing a drug

'Revelatory' study finds a smoking impact that remains after quitting

explore

explore

leisure time

Virginia high school admissions case could be legal follow

Gilead might be held responsible for not developing a drug

Heart attack and stroke risk calculators need revising

Readout LOUD podcast: How biotech is using artificial intelligence

Walensky prepares to leave CDC — and Congress — behind

Testing GLP

Malaria cases in Florida and Texas: Here’s what you need to know

Medical mystery: When a cough is not just a cough

Apple is now the first public company to be valued at $3 trillion

This gene therapy has record $4.25 million price. It's saved children.

hotspot

To avoid data mishandling cases, universities eye AI and other tools

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Diabetes management: Digital health tools fall short, study says

Medical devices makers are asking for forgiveness, not permission

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Why did Pfizer dish out millions for a Super Bowl ad?

hotspot

entertainment

hotspot

focus